Lexeo Therapeutics, Inc. (LXEO): Shareholders' Equity
$246.67M
As of 2025-12-31
$235.06M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $246.67M | +111.1% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $116.84M | +2.9% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $113.53M | n/m | 2025-03-24, Balance as of period end |
| 2022-12-31 | -$112.95M | n/a | 2024-03-11, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $246.67M | +111.1% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $251.33M | +78.5% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $241.54M | +257.6% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $61.01M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $196.08M | -34.6% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $186.29M | +741.1% |
| Alector, Inc. (ALEC) | 2025-12-31 | $30.65M | -75.8% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $11.85M | -70.0% |
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $232.28M | -12.9% |
Compare LXEO, TECX, IVVD, CHRS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗